CD19 and infection: A recent French DESCAR-T registry study reviewing patients with R/R NHL who received CD19 CAR-T therapy found an overall rate of NRM of 5% in the treated population, most of these occurring beyond Day 30, with infections being responsible for the majority (56%) of NRM events.17